The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review
Authors:
- Ryosuke YamauchiRYRyosuke Yamauchi
- Toshihiro ArakiTAToshihiro Araki
- Keiichi MitsuyamaKMKeiichi Mitsuyama
- Takaaki TokitoTTTakaaki Tokito
- Hidenobu IshiiHIHidenobu Ishii
- Shinichiro YoshiokaSYShinichiro Yoshioka
- Kotaro KuwakiKKKotaro Kuwaki
- Atsushi MoriAMAtsushi Mori
- Tetsuhiro YoshimuraTYTetsuhiro Yoshimura
- Osamu TsurutaOTOsamu Tsuruta
- Takuji TorimuraTTTakuji Torimura
Open Access
- 31 August 2018
- journal article
- case report
- Published by Springer Nature in BMC Gastroenterology
- Vol. 18 (1) , 135
Abstract
The use of immune-checkpoint inhibitors in cancer treatment has become increasingly common, resulting in an increase in the incidence of related side effects. Diarrhoea and colitis have been previously documented as gastrointestinal tract-related side effects of immune-checkpoint inhibitors. Although PD-1/PD-L1 inhibitors produce fewer side effects than CTLA-4 inhibitors, diarrhoea and colitis continue to be reported. However, little is known about the endoscopic features associated with PD-1/PD-L1 inhibitors. In this report, we describe three cases of colitis induced by a PD-1 inhibitor nivolumab. These cases showed endoscopic findings characteristic of ulcerative colitis (UC). Treatment was in accordance with UC therapy, which resulted in beneficial outcomes. Three patients with lung cancer treated with nivolumab presented with diarrhoea with (case 2) or without haematochezia (cases 1 and 3). Treatment with nivolumab was ceased and colonoscopy was performed, revealing endoscopic features similar to those of UC. These patients were diagnosed with nivolumab-induced colitis. Case 1 was treated with mesalazine, whereas cases 2 and 3 were treated with corticosteroids. Subsequently, their symptoms improved. Nivolumab-induced colitis exhibited similar characteristics to UC. Treatment was similar to that for UC and was successful.Keywords
This publication has 26 references indexed in Scilit:
- Nivolumab-Induced Colitis Treated by InfliximabClinical Gastroenterology and Hepatology, 2017
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced MelanomaJournal of Clinical Oncology, 2017
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapyCancer Treatment Reviews, 2016
- Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel DiseaseJournal of Crohn's and Colitis, 2016
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- Lymphocytic Colitis Secondary to Ipilimumab TreatmentInflammatory Bowel Diseases, 2013
- Management of Immune-Related Adverse Events and Kinetics of Response With IpilimumabJournal of Clinical Oncology, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras.Journal of Clinical Investigation, 1997
- Inhibition of arachidonic acid release from cells as the biochemical action of anti-inflammatory corticosteroids.Proceedings of the National Academy of Sciences, 1976